{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T09:13:03Z","timestamp":1648977183759},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Geburtshilfe Neonatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n                    Objective Low-molecular-weight heparin (LMWH) is used during pregnancy in\n                    women diagnosed with thrombophilia for prevention of thromboembolic events and\n                    prevention of recurrent pregnancy loss. Prophylactic dosing does not always\n                    achieve target anti-FXa levels of 0.2\u20130.6\u2009IU\/ml. We\n                    aimed to determine if anti-FXa levels, measured in the first trimester, have an\n                    influence on pregnancy outcome.<\/jats:p><jats:p>\n                    Material and Methods Eighty-one first-trimester women with a history of\n                    adverse pregnancy outcomes under LMWH therapy during pregnancy were enrolled in\n                    this study. Anti-FXa levels were measured in the first trimester, and fetal and\n                    maternal outcomes were recorded.<\/jats:p><jats:p>\n                    Results The mean age of women was 28\u00b14 (19\u201340) and mean\n                    anti-FXa level 0.44\u00b10.93\u2009IU\/ml. No bleeding or clotting\n                    complications were associated with LMWH administration. Anti-FXa levels did not\n                    have a relationship with gestational age at birth, fetal weight, type of\n                    delivery, cesarean indications, postpartum bleeding, APGAR scores, or admission\n                    to the neonatal intensive care unit (p&gt;0.005). Anti-FXa levels were not\n                    correlated with live birth rates.<\/jats:p><jats:p>\n                    Conclusion Anti-FXa levels did not have an influence on pregnancy and\n                    fetal outcomes. The effect of LMWH on pregnancy outcomes may not be due to\n                    anticoagulant activity but other mechanisms.<\/jats:p>","DOI":"10.1055\/a-1130-2017","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T13:33:57Z","timestamp":1585834437000},"page":"355-359","source":"Crossref","is-referenced-by-count":0,"title":["Do Anti-Factor Xa Levels have any Impact on Pregnancy Outcome in\n                    Women with Previous Adverse Outcomes?"],"prefix":"10.1055","volume":"224","author":[{"given":"Z. Asli","family":"Oskovi-Kaplan","sequence":"additional","affiliation":[{"name":"Perinatology, Zekai Tahir Burak Health Practice Research Center,\n                    University of Health Sciences, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kudret","family":"Erkenekli","sequence":"additional","affiliation":[{"name":"Perinatology, Zekai Tahir Burak Health Practice Research Center,\n                    University of Health Sciences, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efser","family":"Oztas","sequence":"additional","affiliation":[{"name":"Perinatology, Zekai Tahir Burak Health Practice Research Center,\n                    University of Health Sciences, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seda Bilir","family":"Esmer","sequence":"additional","affiliation":[{"name":"Perinatology, Zekai Tahir Burak Health Practice Research Center,\n                    University of Health Sciences, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuri","family":"Danisman","sequence":"additional","affiliation":[{"name":"Perinatology, Zekai Tahir Burak Health Practice Research Center,\n                    University of Health Sciences, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Uygur","sequence":"additional","affiliation":[{"name":"Perinatology, Zekai Tahir Burak Health Practice Research Center,\n                    University of Health Sciences, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Seval","family":"Ozgu-Erdinc","sequence":"additional","affiliation":[{"name":"Perinatology, Zekai Tahir Burak Health Practice Research Center,\n                    University of Health Sciences, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000467385","article-title":"Thrombogenesis in thrombophilic pregnancy: evaluation of low-molecular-weight\n                    heparin prophylaxis","volume":"137","author":"R Simeone","year":"2017","journal-title":"Acta haematologica"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.21613\/gorm.2016.490","article-title":"Pulmonary Embolism associated with hyperemesis gravidarum two case reports","volume":"23","author":"B Keskink\u0131l\u0131\u00e7","year":"2017","journal-title":"Gynecol Obstet Reprod Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MBC.0000000000000573","article-title":"The value and impact of anti-Xa activity monitoring for prophylactic dose\n                    adjustment of low-molecular-weight heparin during pregnancy: a retrospective\n                    study. Blood Coag","volume":"28","author":"A Boban","year":"2017","journal-title":"Fibrinolysis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.thromres.2009.07.014","article-title":"Analysis of unfractionated heparin dose requirements to target therapeutic\n                    anti-Xa intensity during pregnancy","volume":"125","author":"N P Clark","year":"2010","journal-title":"Thrombosis research"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/imj.13117","article-title":"Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary\n                    hospital","volume":"46","author":"S Petrie","year":"2016","journal-title":"Intern Med J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1097\/AOG.0b013e31818638dc","article-title":"Anti-factor Xa plasma levels in pregnant women receiving low molecular weight\n                    heparin thromboprophylaxis","volume":"112","author":"N S Fox","year":"2008","journal-title":"Obstet Gynecol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11239-016-1409-5","article-title":"Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does\n                    not affect outcomes in pregnant patients with venous thromboembolism","volume":"43","author":"B P McDonnell","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.thromres.2014.09.033","article-title":"A case series of LMWH use in pregnancy: should trough anti-Xa levels guide\n                    dosing?","volume":"134","author":"M Berresheim","year":"2014","journal-title":"Thromb Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/14767050500275796","article-title":"Prophylactic dosing adjustment in pregnancy based upon measurements of\n                    anti-factor Xa levels","volume":"18","author":"C Gyamfi","year":"2005","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/S0140-6736(16)31139-4","article-title":"Low-molecular-weight heparin and recurrent placenta-mediated pregnancy\n                    complications: a meta-analysis of individual patient data from randomised\n                    controlled trials","volume":"388","author":"M A Rodger","year":"2016","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006780.pub3","article-title":"Antithrombotic therapy for improving maternal or infant health outcomes in women\n                    considered at risk of placental dysfunction","author":"J M Dodd","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","first-page":"123","article-title":"Impaired implantation and hereditary thrombophila; expression of LIF (leukemia\n                    inhibitory factor) on extravillous trophoblasts","volume":"18","author":"R Hekimo\u011flu","year":"2012","journal-title":"Gynecol Obstet Reprod Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/15513818809022278","article-title":"Thrombosis of the umbilical cord: analysis of 52 cases and literature\n                    review","volume":"8","author":"S A Heifetz","year":"1988","journal-title":"Pediatr Pathol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e020501.","DOI":"10.1136\/bmjopen-2017-020501","article-title":"Study protocol for a randomised controlled trial: treatment of early\n                    intrauterine growth restriction with low molecular weight heparin (TRACIP)","volume":"8","author":"E Mazarico","year":"2018","journal-title":"BMJ Open"},{"key":"ref16","first-page":"176","article-title":"Recurrent placental abruption with methylenetetrahydrofolate reductase C667t\n                    heterozygosity: a case report","volume":"13","author":"I T\u00fcrk\u00e7\u00fco\u011flu","year":"2007","journal-title":"Gynecol Obstet Reprod Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"196: Thromboembolism in Pregnancy","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/jp.2009.164","article-title":"Fluctuations in anti-factor Xa levels with therapeutic enoxaparin\n                    anticoagulation in pregnancy","volume":"30","author":"E Friedrich","year":"2010","journal-title":"J Perinatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1055\/s-0034-1396899","article-title":"Ineffective treatment of low-molecular-weight heparin in obese subject with\n                    traumatic fractures of the leg","volume":"25","author":"E Imbalzano","year":"2016","journal-title":"Int J Angiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/TA.0b013e3181d32271","article-title":"Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and\n                    increased deep venous thrombosis rates in critically ill trauma and surgical\n                    patients","volume":"68","author":"D Malinoski","year":"2010","journal-title":"J Trauma"},{"key":"ref22","first-page":"22","article-title":"Outcome of obstetric patients admitted to a medical intensive care unit in\n                    Southeastern Turkey","volume":"15","author":"N Uysal","year":"2009","journal-title":"Gynecol Obstet Reprod Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(14)60793-5","article-title":"Antepartum dalteparin versus no antepartum dalteparin for the prevention of\n                    pregnancy complications in pregnant women with thrombophilia (TIPPS): a\n                    multinational open-label randomised trial","volume":"384","author":"M A Rodger","year":"2014","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2018.08.006","article-title":"Tinzaparin for the treatment of foetal growth retardation: an open-labelled\n                    randomized clinical trial","volume":"170","author":"A T Hansen","year":"2018","journal-title":"Thromb Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1160\/TH16-03-0221","article-title":"Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome\n                    in thrombophilic women. A randomised controlled trial","volume":"116","author":"R Salim","year":"2016","journal-title":"Thromb Haemost"},{"key":"ref26","first-page":"3","article-title":"[High risk of recurrent spontaneous abortion during second trimester in women\n                    carriers of polymorphism A2 in platelet glycoprotein IIb\/IIIa]","volume":"47","author":"P Ivanov","year":"2008","journal-title":"Akush Ginekol (Sofiia)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/14767058.2016.1212330","article-title":"Genetic heterogeneity of platelet glycoproteins Ia and IIIa and the risk of\n                    spontaneous miscarriages","volume":"30","author":"N Vlachadis","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3233\/CH-151949","article-title":"Thrombelastometric results and platelet function during pregnancy in women\n                    receiving low molecular weight heparin with a history of recurrent\/late\n                    abortion \u2013 a retrospective analysis","volume":"61","author":"G F von Tempelhoff","year":"2015","journal-title":"Clin Hemorheol Microcirc"}],"container-title":["Zeitschrift f\u00fcr Geburtshilfe und Neonatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1130-2017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T20:52:10Z","timestamp":1608151930000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1130-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":26,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2020,12,4]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1130-2017","relation":{},"ISSN":["0948-2393","1439-1651"],"issn-type":[{"value":"0948-2393","type":"print"},{"value":"1439-1651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}